Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verastem

5.27
+0.17003.33%
Post-market: 5.280.0099+0.19%19:56 EDT
Volume:1.81M
Turnover:9.27M
Market Cap:289.58M
PE:-1.51
High:5.30
Open:5.10
Low:4.86
Close:5.10
Loading ...

Verastem publishes RAMP 201 trial data in Journal of Clinical Oncology

TIPRANKS
·
12 Jul

Verastem Oncology Secures FDA Approval for Avutometinib Plus Defactinib Combination in KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Reuters
·
12 Jul

Verastem Oncology Announces Publication of the Primary Results From the Phase 2 Ramp 201 Trial of Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

THOMSON REUTERS
·
12 Jul

ADVISORY-Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn

Reuters
·
08 Jul

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

THOMSON REUTERS
·
08 Jul

BRIEF-Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
08 Jul

Verastem Oncology Announces Stock Option Inducement Grants for New Employees Under Nasdaq Rule

Reuters
·
08 Jul

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
08 Jul

Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment

TIPRANKS
·
05 Jul

BTIG Remains a Buy on Verastem (VSTM)

TIPRANKS
·
02 Jul

Verastem Oncology Secures FDA Approval for Avutometinib Plus Defactinib in KRAS-Mutated Low-Grade Serous Ovarian Cancer

Reuters
·
01 Jul

Verastem Is Maintained at Outperform by RBC Capital

Dow Jones
·
25 Jun

Verastem Inc : RBC Cuts Target Price to $12 From $16

THOMSON REUTERS
·
25 Jun

RBC Capital Keeps Their Buy Rating on Verastem (VSTM)

TIPRANKS
·
25 Jun

RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk

MT Newswires Live
·
25 Jun

Top Executives Make Significant Moves with Verastem Stock!

TIPRANKS
·
25 Jun

Verastem Inc. CFO Daniel Calkins Reports Disposal of Common Shares

Reuters
·
25 Jun

BRIEF-Verastem Oncology Announces First Patient Dosed With VS-7375, An Oral KRAS G12D Inhibitor, In US Phase 1/2A Trial In KRAS G12D Advanced Solid Tumors

Reuters
·
25 Jun

Verastem announces first patient dosed with VS-7375

TIPRANKS
·
25 Jun

Verastem Oncology Announces First Patient Dosed With VS-7375, an Oral Kras G12d (on/off) Inhibitor, in a U.S. Phase 1/2a Trial in Kras G12d Advanced Solid Tumors

THOMSON REUTERS
·
25 Jun